Finally, Fleischmann and colleagues demonstrated that the addition of TNF-α inhibitors to methotrexate in RA patients with an inadequate response to methotrexate could be associated with a greater likelihood of achieving the American College of Rheumatology 70% response criteria at 6 months compared to the addition of sulfasalazine and hydroxychloroquine [52]. Here, TNF is linked to rheumatoid arthritis.